# Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer

> **NCT02243358** · PHASE2 · COMPLETED · sponsor: **Henry Ford Health System** · enrollment: 24 (actual)

## Conditions studied

- Pancreas Neoplasm Malignant Resectable

## Interventions

- **DRUG:** Folfox6
- **DRUG:** Gemcitabine
- **RADIATION:** Radiation Therapy
- **PROCEDURE:** Pancreaticoduodenectomy with retroperitoneal lymphadenectomy

## Key facts

- **NCT ID:** NCT02243358
- **Lead sponsor:** Henry Ford Health System
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2017-06-28
- **Final completion:** 2020-01-14
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02243358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02243358, "Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02243358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*